Amiloride Hydrochloride as an Effective Treatment for ADHD

NCT ID: NCT01733680

Last Updated: 2018-07-20

Basic Information

• Recruitment Status: TERMINATED
• Clinical Phase: EARLY_PHASE1
• Total Enrollment: 3 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2012-09-30
• Study Completion Date: 2015-09-30

Brief Summary

The investigators are proposing to test a medication derived from our prior studies of the gene SLC9A9. This one gene makes NHE proteins that control how we learn and remember items, which is impaired in ADHD and may cause an inability to plan, prioritize, self-monitor,inhibit, initiate, self-correct, or control one's behavior. The investigators now propose to investigate the therapeutic utility of an NHE inhibitor, amiloride hydrochloride, for the treatment of attention deficit hyperactivity disorder (ADHD) in medication-naïve adults with ADHD.

Detailed Description

Our specific aims and hypotheses are as follows:

Primary Aim: Assess the efficacy and adverse effects of amiloride in medication naive ADHD adults in a placebo controlled study. Hypothesis 1: Amiloride will reduce scores on our primary outcome measure, the Adult Attention-Deficit/Hyperactivity Disorder Investigator Symptom Rating Scale (AISRS) and on our secondary outcome, the ADHD specific Clinical Global Impressions (CGI) improvement scale. Hypothesis 2: Amiloride will be well tolerated and will have few side effects in adults with ADHD.

Exploratory Aim 2: Assess effects of amiloride on ADHD-associated clinical features. We will also assess, in an exploratory manner, the effect of amiloride on two clinical features that are not well treated by current ADHD medications: deficits in emotional self-regulation (DESR) and executive function deficit (EFD). Hypothesis 3 predicts that amiloride treatment will reduce symptoms of DESR and of EFD.

We will recruit 40 adults who are diagnosed with ADHD in a double blind placebo controlled study. 20 subjects will receive amiloride hydrochloride and 20 subjects will receive placebo for 8 weeks. Participation in the study requires subjects to meet with the physician for a screening visit, baseline visit and 8 additional weekly visits.

Conditions

ADHD

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: TRIPLE

Study Groups

Amiloride

Drug: Subjects will take 5mg qd Amiloride for 2 weeks, 10mg qd Amiloride for 3 weeks, 15 mg qd Amiloride for 3 weeks.

Behavioral: Each week subjects will complete the AISRS, BRIEF-A, and CGI.

Group Type: ACTIVE_COMPARATOR

amiloride

Intervention Type: DRUG

Subjects will take either amiloride hydrochloride or placebo for 8 weeks.

Behavioral

Intervention Type: BEHAVIORAL

Each week of the study, subjects will complete the AISRS, BRIEF-A, and CGI to measure symptom improvement

Placebo

Drug: Subjects will take placebo for 8 weeks Behavioral: Each week subjects will complete questionnaires: AISRS, BRIEF-A, and CGI

Group Type: PLACEBO_COMPARATOR

Behavioral

Intervention Type: BEHAVIORAL

Each week of the study, subjects will complete the AISRS, BRIEF-A, and CGI to measure symptom improvement

Interventions

amiloride

Subjects will take either amiloride hydrochloride or placebo for 8 weeks.

Intervention Type: DRUG

Behavioral

Each week of the study, subjects will complete the AISRS, BRIEF-A, and CGI to measure symptom improvement

Intervention Type: BEHAVIORAL

Other Intervention Names

ADHD symptoms, executive function, emotional self-regulation

Eligibility Criteria

Inclusion Criteria

1. Medication naïve male or female adults ages 18-55 years.

2. A diagnosis of DSM-IV ADHD combined type based on clinical assessment by the study psychiatrist using the Conners Adult ADHD Diagnostic Interview;

3. proficiency in English;

4. A baseline score of 24 or more on the AISRS;

5. ability to swallow pills;

6. ability to report reliably, understand the nature of the study and sign an informed consent document as determined by the study psychiatrist

Exclusion Criteria

We will exclude potential participants who:

1. have had pharmacologic treatment for ADHD in the past year;

2. are pregnant or nursing;

3. are Investigators or their immediate family (spouse, parent, child, grandparent, or grandchild);

4. have any serious, unstable medical illness including hepatic, renal, gastroenterological, respiratory, cardiovascular (including ischemic heart disease), endocrinologic, neurologic, immunologic, or hematologic disease;

5. have severe allergies or multiple adverse drug reactions;

6. have a current or past history of seizures;

7. meet current DSM-IV criteria for anxiety or depression or illicit substance abuse in prior six months (these exclusions are feasible because, although the lifetime comorbidity of ADHD with these disorders is high, we and others have shown that the presence of these disorders at the time of ascertainment for adult ADHD studies is less than 10%);

8. are judged by the study psychiatrist to be at serious suicidal risk.

9. have current or past diagnoses of schizophrenia or bipolar disorder;

10. have a history of hypersensitivity to amiloride or drug class members;

11. have a history of hyperkalemia, diabetes mellitus, renal disease or anuria;

12. have renal impairment Cr > 1.5; or

13. are taking potassium supplements, aldosterone antagonists, tacrolimus or ACE inhibitors.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 55 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

State University of New York - Upstate Medical University

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Stephen V Faraone, PhD

Role: PRINCIPAL_INVESTIGATOR

SUNY Upstate Medical Unversity

Prashant Kaul, MD

Role: PRINCIPAL_INVESTIGATOR

VA Medical Center at Syracuse

Locations

SUNY Upstate Medical University

Syracuse, New York, United States

Countries

United States

Other Identifiers

320969

Identifier Type: -

Identifier Source: org_study_id